Evidence movement, dated and sourced.
Short landscape summaries showing what changed in a therapeutic area over a defined window. Each note is pinned to a review date and source-backed. If the evidence has moved in your area, the note shows where — and where it hasn't.
Metabolic 2026-05-17
Metabolic evidence movement (T1D) — regulatory recognition lag
Historical pattern showing evidence movement preceding formal regulatory recognition, with a measurable gap between published evidence and guideline incorporation.
prepare — clinical truth and economic stake approaching thresholds 4 movements documented Neurodegenerative 2026-05-17
Neurodegenerative safety signal assessment — evidence separation
Historical example showing how source-supported safety questions can be separated from public speculation in a neurodegenerative disease context.
monitor — signals visible but not yet convergent across lanes 3 movements documented Alzheimer's disease 2026-05-17
Amyloid-directed therapy landscape movement
Three trial readouts, one regulatory action, and one payer policy shift since the last review window.
active review now — clinical truth and ratification scores support committee review while economic stake holds at threshold 6 movements documentedDon't see your area?
Submit the disputed claim. We confirm fit and scope before any brief is produced.